2007-06: Avastin-Injections in Age Related Macular Degeneration: Prospective Study for Optimal Frequency and Follow-up Determination
Age-related macular degeneration (ARMD) results in a deterioration of the central retinal function, and is the leading cause of blindness in people over 50 years of age in Europe and the USA. The wet form of ARMD, with choroidal neovascularization, is more aggressive and may progress more rapidly to blindness. Lucentis has been registered for treatment of wet ARMD, but Avastin appears to be a cost-effective alternative for Lucentis. An optimal injection schedule has not been determined so far. A reduction of the number of injections, without loss of treatment efficacy, would have a number of beneficial effects: a decrease of the risk associated with intravitreal injection (such as endophthalmitis), cost-effectiveness and reduced ophthalmic work-load. The objective of this randomized, prospective, open-label trial is to determine the optimal patient observation and Avastin injection schedule. Patients will be randomized towards a four-, six- or eight weekly injections and observation interval. The primary endpoint is visual acuity at 12 months.